Found: 16
Select item for more details and to access through your institution.
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia.
- Published in:
- Medicine International (2754-3242), 2022, v. 2, n. 2, p. 1, doi. 10.3892/mi.2022.32
- By:
- Publication type:
- Article
Clinical applicability and prognostic significance of molecular response assessed by fluorescent- PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/ PETHEMA study.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 5, p. 581, doi. 10.1111/bjh.12576
- By:
- Publication type:
- Article
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 586, doi. 10.1002/ajh.27227
- By:
- Publication type:
- Article
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 438, doi. 10.3390/cancers15020438
- By:
- Publication type:
- Article
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2817, doi. 10.3390/cancers14112817
- By:
- Publication type:
- Article
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092342
- By:
- Publication type:
- Article
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4622, doi. 10.3390/cancers13184622
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
P-148: Real-life analysis of the multiple myeloma patient's survival in a third-level hospital.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S116, doi. 10.1016/S2152-2650(21)02275-8
- By:
- Publication type:
- Article
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00835-5
- By:
- Publication type:
- Article
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00835-5
- By:
- Publication type:
- Article
Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 6, p. 631, doi. 10.1002/ajh.23167
- By:
- Publication type:
- Article
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
- Published in:
- British Journal of Haematology, 2008, v. 142, n. 5, p. 766, doi. 10.1111/j.1365-2141.2008.07263.x
- By:
- Publication type:
- Article
A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 12, p. 2003, doi. 10.1002/cncr.33403
- By:
- Publication type:
- Article